Yuanlin Xia, Guihua Huang Department of Anesthesiology, Guizhou Hospital of Beijing Jishuitan Hospital, Guiyang, Guizhou Province, 550014, Peopleâs Republic of ChinaCorrespondence: Guihua Huang, Email 435141387@qq.comAbstract: Cancer pain significantly impairs quality of life in oncology patients and remains inadequately managed globally. This narrative review examines the pharmacokinetic and pharmacodynamic properties of oxycodone, the impact of CYP2D6 genetic polymorphism on its metabolism, and the EGFR-dependent bidirectional effects of oxycodone on cancer cell biology. Critically, these bidirectional tumor cell effects were observed exclusively under supraphysiological in vitro concentrations (0.01â 10 μM), far exceeding clinical therapeutic plasma levels (nM range), and are insufficient to alter current clinical guidelines. We further evaluate oxycodoneâs effects on tumor angiogenesis and immune function, and summarize clinical evidence from postoperative analgesia studies in breast, colorectal, gastric, lung, and liver cancer patients, supporting oxycodone as a preferred option for perioperative analgesia in abdominal and thoracic cancer surgery. The limitations of oxycodone in chronic neuropathic and bone metastasis pain are discussed, alongside recent advances in oxycodone formulation development and novel analgesics in China. Individualized treatment strategies integrating pharmacogenomic profiles and multimodal approaches are encouraged.Keywords: oxycodone, cancer pain, postoperative analgesia, pharmacological effects, mechanism of action, drug comparison
Xia et al. (Wed,) studied this question.